Navigation Links
Takeda to Acquire Nycomed
Date:5/18/2011

Takeda's European sales," said Yasuchika Hasegawa, President & CEO of Takeda. "Nycomed's strength in a geographically wide range of markets and its diverse talent base will be a strong driver to helping us realize our important mission of striving toward better health for patients worldwide through leading innovation in medicine."

Nycomed, headquartered in Zurich, Switzerland, is a privately-owned pharmaceutical company with strong presence in Europe and emerging markets. Nycomed's diversified product portfolio includes both established prescription pharmaceutical products as a primary revenue driver, and over the counter (OTC) products. It has a strong European commercial network and is aggressively growing in emerging markets which account for more than 50 percent of global pharmaceutical growth. Its key success factors include the utilization of its broad product range and the application of commercialization and development strategies that fit with the market environment and medical needs in each individual country and region.

"The combination of Takeda's successful track record of innovation with Nycomed's efficient commercialization and manufacturing infrastructure will create a global player with a phenomenal ability to bring medicines to patients and healthcare providers around the world," said Hakan Bjorklund, Chief Executive Officer of Nycomed.

Through the addition of Nycomed's remarkable entrepreneurial corporate culture to Takeda's corporate culture, nurtured for more than two centuries, Takeda is aiming to become a truly global pharmaceutical company with a diversified talent base capable of conducting global business effectively.

Since being acquired by Nordic Capital along with co-investors in 2005, Nycomed has followed an aggressive growth strategy that has propelled the company to an international player with a broad and strong market presence.

"The investment in Nycomed has outperformed even the highest e
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
11. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 Aethlon Medical, Inc. ... address infectious diseases and cancer, today announced that ... to present a corporate overview at the 27th Annual ... Hotel in Laguna Niguel, California . ... ( http://www.roth.com/main/page.aspx?PageID=7207 ). A live webcast of ...
(Date:3/4/2015)...  Kannalife Sciences, Inc. ("Kannalife") announces that Dr. ... Board to assist the Company in the advancement of ... cannabinoid therapeutics for the treatment of Chronic Traumatic Encephalopathy ... conducting the full autopsy of Mike Webster , ... Pittsburgh Steelers. It was through his examination of ...
(Date:3/4/2015)... March 4, 2015  Heska Corporation (Nasdaq: ... You to Join Its Fourth Quarter and Year End ... 2015 @ 9:00 a.m. (MST) / 11:00 a.m. (EST)Where: ... 2014 Earnings Call link on the front page of ... to the web at the address above.  Alternatively, you ...
Breaking Medicine Technology:Aethlon Medical to Present at the 27th Annual ROTH Conference 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 3Webcast Alert: Heska Announces Fourth Quarter and Year End 2014 Earnings Conference Call Webcast 2
... /PRNewswire-FirstCall/ -- Kosan,Biosciences Incorporated announced data will be ... its Hsp90,inhibitor, epothilone and nuclear export inhibitor programs, ... for Cancer Research,(AACR), being held in Los Angeles, ... programs are as follows. The,location for all poster ...
... April 10, 2007--In a study appearing in the ... by the,National Institutes of Healths National Institute of ... a,connection between a specific gene and the inflammatory ... of autoimmune,diseases. , Vitiligo is a chronic condition ...
Cached Medicine Technology:Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 2Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 3Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 2Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 3
(Date:3/4/2015)... (PRWEB) March 05, 2015 The ... a value of $5,632.8 million by 2019, at ... of 2014 to 2019. , Browse through the ... analysis of industry trends and segments, with the ... , Phthalic Anhydride (PA) is a derivative ...
(Date:3/4/2015)... 2015 Dr. Christopher Asandra, M.D., Founder ... today lamented the FDA’s recent decision to issue ... He argued that FDA’s conclusions are not supported by ... suffer from testosterone deficiency. , “The FDA appears to ... replacement therapy,” said Dr. Asandra. “There is not nearly ...
(Date:3/4/2015)... 04, 2015 FDA’s New Inspection Approach:, ... Webinar**, March 24, 2015 — 1:30 p.m. – 3:00 ... know within four hours of an inspection whether a ... on their “good” list, they’ll merely ask for reassurance ... is on the “bad” list, the manufacturer must get ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Smokers across ... marketing campaign called 'We Love Smokers' from Aqua-Tine, the ... tobacco. , "It’s important to establish a clear ... to it. Our idea, 'We Love Smokers' elevates the ... of view. We created a bold tone of voice ...
(Date:3/4/2015)... March 04, 2015 More than a ... risks potentially associated with low testosterone treatments ( http://www.testosteronelawsuithub.com/ ... that it will now require manufacturers to warn patients ... for heart attacks and strokes. In a Drug ... also stated that it was requiring testosterone manufacturers to ...
Breaking Medicine News(10 mins):Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 2Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 3Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 2Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4
... HealthDay Reporter , FRIDAY, June 25 (HealthDay News) -- At ... her back and leg. An Army captain, helicopter pilot and ... But as her Iraq deployment continued, the pain ... stabbed. She could hardly sit, stand or walk, let alone ...
... A mechanism that regulates stem-cell differentiation in mice ... degenerative disease in humans, according to a Penn ... involved manipulating a protein called STAT3 that signals ... a specialized type of cell or self-renew and ...
... the Robert Wood Johnson Foundation have awarded 10 ... to contribute to the field of public health ... receive $1,000 for registration and travel to attend ... Group Annual Meeting, June 27-June 30, 2010, in ...
... SALT LAKE CITY Using an experimental mouse model ... that adding antioxidant therapy to traditional antimalarial treatment may ... were published online June 24, 2010, in the journal ... by parasites that invade liver and red blood cells, ...
... America (GSA) the nation,s largest interdisciplinary organization devoted ... Fung, PhD, of the Chinese University of Hong Kong ... Paul B. Baltes Foundation Award in Behavioral and Social ... early career contributions in behavioral and social gerontology. ...
... ENT and ... “Holes in My Shoes.” The film made its broadcast premier last Holiday Season on ... at 10pm. , ... (Vocus) June 25, 2010 -- ENT and Allergy Associates, LLP (ENTA) is proud to ...
Cached Medicine News:Health News:Chronic Pain Often Follows U.S. Soldiers Home: Study 2Health News:Chronic Pain Often Follows U.S. Soldiers Home: Study 3Health News:Mechanism that may trigger degenerative disease identified 2Health News:Antioxidants may help prevent malaria complicaton that leads to learning impairment 2Health News:Antioxidants may help prevent malaria complicaton that leads to learning impairment 3Health News:Fung to receive GSA's 2010 Baltes Foundation Award 2Health News:ENT and Allergy Associates Sponsors Award Winning PBS Documentary 2
The cardiac blanket is pre-positioned at the waist during prep, unrolled upon closure of the saphenous vein graft incision, and inflated post-bypass....
The adult blanket provides full coverage for patients of all sizes. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also reduces ...
The cath lab blanket, designed for use in the Cardiac Cath Lab, surrounds the patient with warm air and allows unrestricted access to the femoral artery....
The Bair Hugger outpatient blanket makes it easy to give your patients the benefit of prewarming and enhance patient comfort during outpatient procedures....
Medicine Products: